Jon Stoessl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7075033/publications.pdf Version: 2024-02-01



ION STOFSSI

#	Article	IF	CITATIONS
1	What's New at the Journal in 2022. Movement Disorders, 2022, 37, 1-2.	3.9	2
2	Cortical morphology predicts placebo response in multiple sclerosis. Scientific Reports, 2022, 12, 732.	3.3	0
3	Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. Movement Disorders, 2021, 36, 389-397.	3.9	13
4	Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US. Npj Parkinson's Disease, 2021, 7, 21.	5.3	14
5	Dopamine Receptors in Parkinson's Disease: A Metaâ€Analysis of Imaging Studies. Movement Disorders, 2021, 36, 1781-1791.	3.9	40
6	Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease. JAMA Neurology, 2021, 78, 1262.	9.0	70
7	2021: Looking Forward. Movement Disorders, 2021, 36, 11-12.	3.9	0
8	Optical coherence tomography of patients with Parkinson's disease and progressive supranuclear palsy. Clinical Neurology and Neurosurgery, 2020, 189, 105635.	1.4	9
9	COVID-19 and selective vulnerability to Parkinson's disease. Lancet Neurology, The, 2020, 19, 719.	10.2	43
10	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	2.8	63
11	Movement Disorders in the World of <scp>COVID</scp> â€19. Movement Disorders, 2020, 35, 709-710.	3.9	27
12	Deception and the ethics of placebo. International Review of Neurobiology, 2020, 153, 147-163.	2.0	2
13	Immunotherapy for Parkinson's disease: stay tuned. Lancet Neurology, The, 2020, 19, 561-562.	10.2	0
14	Novel data-driven, equation-free method captures spatio-temporal patterns of neurodegeneration in Parkinson's disease: Application of dynamic mode decomposition to PET. NeuroImage: Clinical, 2020, 25, 102150.	2.7	4
15	<i>Movement Disorders</i> : New Faces, Same Journal. Movement Disorders, 2020, 35, 1-2.	3.9	14
16	Movement Disorders in the World of <scp>COVID</scp> â€19. Movement Disorders Clinical Practice, 2020, 7, 355-356.	1.5	18
17	Striatal DAT SPECT: Caveat Emptor!. Movement Disorders, 2019, 34, 1430-1432.	3.9	6
18	Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease. Movement Disorders, 2019, 34, 1891-1900.	3.9	99

#	Article	IF	CITATIONS
19	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. Movement Disorders, 2019, 34, 1406-1422.	3.9	62
20	Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner. Parkinsonism and Related Disorders, 2019, 66, 189-194.	2.2	1
21	Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations. NeuroImage: Clinical, 2019, 23, 101856.	2.7	21
22	Occult central pontine myelinolysis post liver transplant: A consequence of pre-transplant hyponatremia. Annals of Hepatology, 2019, 18, 651-654.	1.5	2
23	Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 301-313.	2.8	89
24	Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain, 2019, 142, 512-525.	7.6	194
25	<i>Movement Disorders</i> Journal: Yesterday, Today, Tomorrow, and Always. Movement Disorders, 2019, 34, 1814-1816.	3.9	1
26	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. Journal of Parkinson's Disease, 2019, 9, 31-61.	2.8	45
27	The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. Lancet Neurology, The, 2018, 17, 309-316.	10.2	57
28	Dyskinesias and levodopa therapy: why wait?. Journal of Neural Transmission, 2018, 125, 1119-1130.	2.8	10
29	Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. PLoS ONE, 2018, 13, e0206607.	2.5	14
30	Operationalizing Neuroimaging for Disorders of Consciousness in the Canadian Context. Canadian Journal of Neurological Sciences, 2018, 45, 633-635.	0.5	0
31	Win-Concurrent Sensory Cues Can Promote Riskier Choice. Journal of Neuroscience, 2018, 38, 10362-10370.	3.6	32
32	Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study. Movement Disorders, 2018, 33, 1945-1950.	3.9	37
33	PET Molecular Imaging in Familial Parkinson's Disease. International Review of Neurobiology, 2018, 142, 177-223.	2.0	6
34	Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going. Movement Disorders, 2018, 33, 1213-1227.	3.9	34
35	Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. NeuroImage: Clinical, 2018, 19, 652-660.	2.7	23
36	PBB3 binding in a patient with corticobasal syndrome. Movement Disorders, 2018, 33, 1359-1360.	3.9	7

#	Article	IF	CITATIONS
37	Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Current Medical Research and Opinion, 2018, 34, 2063-2073.	1.9	152
38	Conclusions. Movement Disorders, 2018, 33, 701-701.	3.9	0
39	Gender differences in Parkinson's disease depression. Parkinsonism and Related Disorders, 2017, 36, 93-97.	2.2	34
40	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	3.9	88
41	Editors' Note: The 200th <scp>A</scp> nniversary of the <scp>S</scp> haking <scp>P</scp> alsy. Movement Disorders, 2017, 32, 1-1.	3.9	16
42	Glucose utilization: still in the synapse. Nature Neuroscience, 2017, 20, 382-384.	14.8	56
43	Reversible Parkinsonism and Rapidly Progressive Dementia Due to Dural Arteriovenous Fistula: Case Series and Literature Review. Movement Disorders Clinical Practice, 2017, 4, 607-611.	1.5	12
44	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a <scp>P</scp> arkinson disease patient. Annals of Neurology, 2017, 81, 46-57.	5.3	72
45	PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins. Movement Disorders, 2017, 32, 1016-1024.	3.9	62
46	The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. Translational Neurodegeneration, 2017, 6, 4.	8.0	19
47	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurology, The, 2017, 16, 351-359.	10.2	96
48	Challenges and unfulfilled promises in Parkinson's disease. Lancet Neurology, The, 2017, 16, 866-867.	10.2	4
49	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 2017, 32, 1264-1310.	3.9	608
50	<i>DNAJC12</i> and dopaâ€responsive nonprogressive parkinsonism. Annals of Neurology, 2017, 82, 640-646.	5.3	60
51	Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. Neurobiology of Aging, 2017, 57, 248.e7-248.e12.	3.1	83
52	Tau imaging in progressive supranuclear palsy. Movement Disorders, 2017, 32, 91-93.	3.9	7
53	Raul de la Fuenteâ€Fernandez, February 22, 1959–May 11, 2016. Movement Disorders, 2016, 31, 1144-1145.	3.9	0
54	A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. Movement Disorders, 2016, 31, 405-409.	3.9	14

#	Article	IF	CITATIONS
55	Ethical and Clinical Considerations at the Intersection of Functional Neuroimaging and Disorders of Consciousness. Cambridge Quarterly of Healthcare Ethics, 2016, 25, 613-622.	0.8	9
56	ls Axonal Degeneration a Key Early Event in Parkinson's Disease?. Journal of Parkinson's Disease, 2016, 6, 703-707.	2.8	36
57	Salivary gland biopsy for diagnosis of Parkinson's disease?. Lancet Neurology, The, 2016, 15, 654-656.	10.2	7
58	DCTN1 p.K56R in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 28, 56-61.	2.2	27
59	Reply to letter to the editor: Is there anything more to learn from SWEDD?. Movement Disorders, 2016, 31, 1426-1428.	3.9	0
60	Movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 136, 957-969.	1.8	11
61	Optimizing diagnosis in Parkinson's disease: Radionuclide imaging. Parkinsonism and Related Disorders, 2016, 22, S47-S51.	2.2	22
62	Comment: Increased D ₃ binding—A substrate for levodopa-induced dyskinesias?. Neurology, 2016, 86, 228-228.	1.1	3
63	The role of biomarkers and imaging in Parkinson's disease. Expert Review of Neurotherapeutics, 2016, 16, 187-203.	2.8	12
64	The Saskatchewan Movement Disorders Program: Commitment Pays Off. Canadian Journal of Neurological Sciences, 2015, 42, 70-71.	0.5	0
65	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. JAMA Neurology, 2015, 72, 100.	9.0	272
66	Canadian Perspectives on the Clinical Actionability of Neuroimaging in Disorders of Consciousness. Canadian Journal of Neurological Sciences, 2015, 42, 96-105.	0.5	8
67	Imaging in Parkinson's disease: time to look below the neck. Brain, 2015, 138, 512-514.	7.6	2
68	<i>DNAJC13</i> genetic variants in parkinsonism. Movement Disorders, 2015, 30, 273-278.	3.9	42
69	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology, 2015, 132, 96-168.	5.7	379
70	Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathologica Communications, 2015, 3, 7.	5.2	74
71	Central pharmacokinetics of levodopa: Lessons from imaging studies. Movement Disorders, 2015, 30, 73-79.	3.9	11
72	Imaging of Dopamine and Serotonin Receptors and Transporters. , 2014, , 241-264.		0

#	Article	IF	CITATIONS
73	In vivo dopaminergic and serotonergic dysfunction in <i>DCTN1</i> gene mutation carriers. Movement Disorders, 2014, 29, 1197-1201.	3.9	15
74	Behavioral Deficits and Striatal DA Signaling in LRRK2 p.G2019S Transgenic Rats: A Multimodal Investigation Including PET Neuroimaging. Journal of Parkinson's Disease, 2014, 4, 483-498.	2.8	32
75	Gene therapy for Parkinson's disease: a step closer?. Lancet, The, 2014, 383, 1107-1109.	13.7	16
76	Developments in neuroimaging: positron emission tomography. Parkinsonism and Related Disorders, 2014, 20, S180-S183.	2.2	12
77	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. Movement Disorders Clinical Practice, 2014, 1, 67-69.	1.5	14
78	SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics, 2014, 15, 23-30.	1.4	56
79	DNAJC13 mutations in Parkinson disease. Human Molecular Genetics, 2014, 23, 1794-1801.	2.9	258
80	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. Parkinsonism and Related Disorders, 2014, 20, 1129-1134.	2.2	6
81	The effects of exercise on cognition in Parkinson's disease: a systematic review. Translational Neurodegeneration, 2014, 3, 5.	8.0	139
82	Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet, The, 2014, 384, 532-544.	13.7	129
83	Imaging in multiple system atrophy. Neurology and Clinical Neuroscience, 2014, 2, 178-187.	0.4	10
84	Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. Movement Disorders, 2014, 29, 1684-1687.	3.9	20
85	DATâ€SPECT diagnoses dopamine depletion, but not PD. Movement Disorders, 2014, 29, 1705-1706.	3.9	16
86	A brain network response to sham surgery. Journal of Clinical Investigation, 2014, 124, 3285-3288.	8.2	2
87	Insights into LRRK2-Mutation Related PD from PET Imaging Studies. , 2014, , 123-124.		0
88	Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis. , 2014, , 161.		0
89	Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. , 2013, 140, 306-318.		50
90	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism and Related Disorders, 2013, 19, 869-877.	2.2	119

#	Article	IF	CITATIONS
91	Decisions under risk in Parkinson's disease: Preserved evaluation of probability and magnitude. Neuropsychologia, 2013, 51, 2679-2689.	1.6	10
92	Novel spatial analysis method for PET images using 3D moment invariants: Applications to Parkinson's disease. NeuroImage, 2013, 68, 11-21.	4.2	18
93	Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. EJNMMI Research, 2013, 3, 69.	2.5	20
94	Biomarkers for trials of neuroprotection in Parkinson's disease. Movement Disorders, 2013, 28, 71-85.	3.9	22
95	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology, 2013, 81, 1322-1331.	1.1	60
96	Neurology in Canada: History of the Canadian Neurological Society. Neurology, 2013, 80, 406-408.	1.1	2
97	Alphaâ€synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Movement Disorders, 2013, 28, 811-813.	3.9	545
98	<i>In-vivo</i> Measurement of LDOPA Uptake, Dopamine Reserve and Turnover in the Rat Brain Using [¹⁸ F]FDOPA PET. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 59-66.	4.3	33
99	The Nature of Progression in Parkinson's Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling. PLoS ONE, 2013, 8, e76595.	2.5	30
100	Neuroimaging of Sleep and Sleep Disorders. , 2013, , .		4
101	Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. Neurology, 2012, 78, 649-657.	1.1	85
102	Cerebrospinal fluid amyloid β and tau in <i>LRRK2</i> mutation carriers. Neurology, 2012, 78, 55-61.	1.1	39
103	Neuroimaging in Parkinson's disease: from pathology to diagnosis. Parkinsonism and Related Disorders, 2012, 18, S55-S59.	2.2	39
104	Imaging striatal dopaminergic function in <i>Phospholipase A2 Group VI</i> –related parkinsonism. Movement Disorders, 2012, 27, 1698-1699.	3.9	14
105	DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiology of Aging, 2012, 33, 836.e5-836.e7.	3.1	34
106	Imaging neural correlates of mild cognitive impairment in Parkinson's disease. Lancet Neurology, The, 2012, 11, 653-655.	10.2	11
107	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS ONE, 2012, 7, e43099.	2.5	44
108	Neuroimaging: Current role in detecting preâ€motor Parkinson's disease. Movement Disorders, 2012, 27, 634-643.	3.9	26

#	Article	IF	CITATIONS
109	Neuroimaging in the early diagnosis of neurodegenerative disease. Translational Neurodegeneration, 2012, 1, 5.	8.0	30
110	Ethical Issues In The Management Of Parkinsonâ \in MS Disease. , 2011, , .		1
111	Liquid Xenon Detectors for Positron Emission Tomography. Journal of Physics: Conference Series, 2011, 312, 062006.	0.4	1
112	Movement disorders: new insights into Parkinson's disease. Lancet Neurology, The, 2011, 10, 5-7.	10.2	3
113	Advances in imaging in Parkinson's disease. Lancet Neurology, The, 2011, 10, 987-1001.	10.2	99
114	Neuroimaging in Parkinson's Disease. Neurotherapeutics, 2011, 8, 72-81.	4.4	59
115	Milestones in neuroimaging. Movement Disorders, 2011, 26, 868-978.	3.9	9
116	Ageâ€specific progression of nigrostriatal dysfunction in Parkinson's disease. Annals of Neurology, 2011, 69, 803-810.	5.3	197
117	Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain, 2011, 134, 3290-3298.	7.6	133
118	A family with parkinsonism, essential tremor, restless legs syndrome, and depression. Neurology, 2011, 76, 1623-1630.	1.1	29
119	Advances in the Role of Neuroimaging to Monitor Disease Progression in Parkinson's Disease. European Neurological Review, 2011, 6, 161.	0.5	0
120	Dopaminergic Imaging in Parkinson's Disease: PET. , 2011, , 3-10.		0
121	Continuous dopaminergic therapy in Parkinson disease: Time to stride back?. Annals of Neurology, 2010, 68, 3-5.	5.3	8
122	Scans without evidence of dopamine deficiency: The triumph of careful clinical assessment. Movement Disorders, 2010, 25, 529-530.	3.9	20
123	Dopamine turnover increases in asymptomatic <i>LRRK2</i> mutations carriers. Movement Disorders, 2010, 25, 2717-2723.	3.9	103
124	Dopamine transporter PET in normal aging: Dopamine transporter decline and its possible role in preservation of motor function. Synapse, 2010, 64, 146-151.	1.2	46
125	Response to Heat Pain Stimulation in Idiopathic Parkinson's Disease. Pain Medicine, 2010, 11, 834-840.	1.9	32

#	Article	IF	CITATIONS
127	Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease. Archives of General Psychiatry, 2010, 67, 857.	12.3	244
128	Effect of electroconvulsive therapy on brain 5-HT ₂ receptors in major depression. British Journal of Psychiatry, 2010, 196, 474-479.	2.8	76
129	Parkin and Parkinson's disease: Differentiated by non-dopaminergic dysfunction?. Experimental Neurology, 2010, 225, 48-50.	4.1	0
130	Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Progress in Brain Research, 2010, 184, 177-192.	1.4	21
131	Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?. Nature Clinical Practice Neurology, 2009, 5, 10-11.	2.5	7
132	PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology, 2009, 72, 1211-1216.	1.1	104
133	Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain, 2009, 132, 2970-2979.	7.6	223
134	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind videoâ€based analysis. Movement Disorders, 2009, 24, 336-343.	3.9	84
135	Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse, 2009, 63, 713-716.	1.2	50
136	DCTN1 mutations in Perry syndrome. Nature Genetics, 2009, 41, 163-165.	21.4	285
137	Dopamine transporter relation to levodopaâ€derived synaptic dopamine in a rat model of Parkinson's: an <i>in vivo</i> imaging study. Journal of Neurochemistry, 2009, 109, 85-92.	3.9	50
138	Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism and Related Disorders, 2009, 15, 281-286.	2.2	89
139	Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism and Related Disorders, 2009, 15, 300-306.	2.2	98
140	Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism and Related Disorders, 2009, 15, 539-541.	2.2	27
141	Functional imaging studies of non-motoric manifestations of Parkinson's Disease. Parkinsonism and Related Disorders, 2009, 15, S13-S16.	2.2	17
142	Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Annals of Neurology, 2008, 63, 388-394.	5.3	62
143	Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype) Tj ETQq1 1 0.784 Neurology, The, 2008, 7, 400-408.	314 rgBT 10.2	/Overlock 1 529
144	Invited Article: Functional imaging in Parkinson disease. Neurology, 2008, 70, 1478-1488.	1.1	70

#	Article	IF	CITATIONS
145	Potential therapeutic targets for Parkinson's disease. Expert Opinion on Therapeutic Targets, 2008, 12, 425-436.	3.4	15
146	Progression of dopaminergic dysfunction in a <i>LRRK2</i> kindred. Neurology, 2008, 71, 1790-1795.	1.1	112
147	LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism. , 2008, , 75-89.		0
148	Gene therapy for Parkinson's disease: early data. Lancet, The, 2007, 369, 2056-2058.	13.7	15
149	Positron emission tomography in premotor Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S421-S424.	2.2	46
150	Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Annals of Neurology, 2007, 62, 468-474.	5.3	121
151	Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Movement Disorders, 2007, 22, 359-365.	3.9	48
152	Joubert syndrome surviving to adulthood associated with a progressive movement disorder. Movement Disorders, 2007, 22, 262-264.	3.9	5
153	Is there seasonal variation in risk of Parkinson's disease?. Movement Disorders, 2007, 22, 1097-1101.	3.9	11
154	Tenâ€year followâ€up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders, 2007, 22, 2409-2417.	3.9	221
155	Understanding the Placebo Effect: Contributions from Neuroimaging. Molecular Imaging and Biology, 2007, 9, 176-185.	2.6	69
156	Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia. Neurology, 2006, 66, 1588-1590.	1.1	69
157	GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurology, The, 2006, 5, 200-202.	10.2	35
158	Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies. Movement Disorders, 2006, 21, 970-975.	3.9	13
159	Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Movement Disorders, 2006, 21, 1457-1461.	3.9	102
160	Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology, 2006, 59, 459-466.	5.3	890
161	Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain, 2006, 129, 1050-1058.	7.6	76
162	Autosomal dominant dystonia-plus with cerebral calcifications. Neurology, 2006, 67, 620-625.	1.1	40

#	Article	IF	CITATIONS
163	Imaging of the Parkinsonian Brain in Relation to Restorative Therapy. , 2006, , 119-130.		0
164	PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain, 2005, 128, 2777-2785.	7.6	242
165	Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease. Canadian Journal of Neurological Sciences, 2005, 32, 277-286.	0.5	4
166	Treatment for the progression of Parkinson's disease. Lancet Neurology, The, 2005, 4, 206.	10.2	5
167	Hot spots: Can positron emission tomography offer insights into the pathogenesis of PD?. Annals of Neurology, 2005, 57, 161-162.	5.3	3
168	Positron emission tomography after fetal transplantation in Huntington's disease. Annals of Neurology, 2005, 58, 331-337.	5.3	57
169	On the Use of Clusters to Determine Environmental Influence on Disease—Reply. Archives of Neurology, 2005, 62, 331.	4.5	0
170	Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Molecular Brain Research, 2005, 134, 24-33.	2.3	43
171	The placebo response as a reward mechanism. Seminars in Pain Medicine, 2005, 3, 37-42.	0.4	24
172	Positron Emission Tomography in Parkinson's Disease. , 2005, , 25-35.		2
173	Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain, 2004, 127, 888-899.	7.6	106
174	Clustering of Parkinson Disease. Archives of Neurology, 2004, 61, 1057-60.	4.5	29
175	Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 869-876.	4.3	81
176	The biochemical bases of the placebo effect. Science and Engineering Ethics, 2004, 10, 143-150.	2.9	33
177	Tremor induced by thalamic deep brain stimulation in patients with complex regional facial pain. Movement Disorders, 2004, 19, 933-936.	3.9	22
178	Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Movement Disorders, 2004, 19, 622-629.	3.9	127
179	Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain, 2004, 127, 2747-2754.	7.6	361
180	Impact of the Spatial Normalization Template and Realignment Procedure on the SPM Analysis of [11C]Raclopride PET Studies. IEEE Transactions on Nuclear Science, 2004, 51, 205-211.	2.0	4

#	Article	IF	CITATIONS
181	Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biological Psychiatry, 2004, 56, 67-71.	1.3	119
182	Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology. Neuron, 2004, 44, 601-607.	8.1	2,653
183	The PARK8 Locus in Autosomal Dominant Parkinsonism: Confirmation of Linkage and Further Delineation of the Disease-Containing Interval. American Journal of Human Genetics, 2004, 74, 11-19.	6.2	195
184	Willing oneself better on placebo—effective in its own right. Lancet, The, 2004, 364, 227-228.	13.7	27
185	Lack of Regional Selectivity During the Progression of Parkinson Disease. Archives of Neurology, 2004, 61, 1920-5.	4.5	47
186	Neural transplantation for the treatment of Parkinson's disease. Lancet Neurology, The, 2003, 2, 437-445.	10.2	322
187	Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. Movement Disorders, 2003, 18, 157-162.	3.9	151
188	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REALâ€₽ET study. Annals of Neurology, 2003, 54, 93-101.	5.3	820
189	A doubleâ€blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology, 2003, 54, 403-414.	5.3	1,450
190	Age and severity of nigrostriatal damage at onset of Parkinson's disease. Synapse, 2003, 47, 152-158.	1.2	33
191	VMAT2 binding is elevated in dopa-responsive dystonia: Visualizing empty vesicles by PET. Synapse, 2003, 49, 20-28.	1.2	69
192	Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Experimental Neurology, 2003, 184, 68-79.	4.1	166
193	Agonizing over dopaminergic replacement therapy—lessons from animal models of parkinson's disease. Experimental Neurology, 2003, 183, 1-3.	4.1	4
194	Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience, 2003, 116, 307-314.	2.3	43
195	Central administration of the neurotensin receptor antagonist sr48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience, 2003, 119, 547-555.	2.3	16
196	[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain, 2003, 126, 2648-2655.	7.6	63
197	Etiology of Parkinson's Disease. Canadian Journal of Neurological Sciences, 2003, 30, S10-S18.	0.5	47
198	PET Study of [18F]6-Fluoro-l-Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium. American Journal of Psychiatry, 2002, 159, 768-774.	7.2	123

#	Article	IF	CITATIONS
199	Bilateral human fetal striatal transplantation in Huntington's disease. Neurology, 2002, 58, 687-695.	1.1	234
200	SCA-2 presenting as parkinsonism in an Alberta family. Neurology, 2002, 59, 1625-1627.	1.1	113
201	Parkinson's disease: imaging update. Current Opinion in Neurology, 2002, 15, 477-482.	3.6	23
202	"Stiff in the Closetâ€+ Who Provides Care for Parkinsonian Patients?. Canadian Journal of Neurological Sciences, 2002, 29, 203-204.	0.5	0
203	Rett Syndrome: Investigation of Nine Patients, including PET Scan. Canadian Journal of Neurological Sciences, 2002, 29, 345-357.	0.5	36
204	PET Study of the Effects of Valproate on Dopamine D2Receptors in Neuroleptic- and Mood-Stabilizer-Naive Patients With Nonpsychotic Mania. American Journal of Psychiatry, 2002, 159, 1718-1723.	7.2	86
205	Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats. Neuroscience, 2002, 112, 261-266.	2.3	11
206	Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience, 2002, 112, 851-859.	2.3	21
207	The placebo effect in Parkinson's disease. Trends in Neurosciences, 2002, 25, 302-306.	8.6	138
208	Dopamine release in human ventral striatum and expectation of reward. Behavioural Brain Research, 2002, 136, 359-363.	2.2	303
209	The placebo effect in neurological disorders. Lancet Neurology, The, 2002, 1, 85-91.	10.2	164
210	[¹⁸ F]â€Dopa positron emission tomography imaging in earlyâ€stage, nonâ€parkin juvenile parkinsonism. Movement Disorders, 2002, 17, 789-794.	3.9	17
211	Increase in Dopamine Turnover Occurs Early in Parkinson's Disease: Evidence from a New Modeling Approach to PET 18F-Fluorodopa Data. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 232-239.	4.3	117
212	The Biochemical Bases for Reward. Evaluation and the Health Professions, 2002, 25, 387-398.	1.9	52
213	Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease. Science, 2001, 293, 1164-1166.	12.6	885
214	Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal) Tj ETQq0 0 and Related Disorders, 2001, 7, 81-88.	0 rgBT /Ον 2.2	erlock 10 Tf 5 27
215	Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA Ki. Parkinsonism and Related Disorders, 2001, 7, 305-309.	2.2	45
216	Daytime somnolence in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2001, 7, 283-286.	2.2	42

#	Article	IF	CITATIONS
217	Positron emission tomography of dopamine pathways in familial Parkinsonian syndromes. Parkinsonism and Related Disorders, 2001, 8, 51-56.	2.2	8
218	Antisense strategies for the treatment of neurological disease. Expert Opinion on Therapeutic Patents, 2001, 11, 547-562.	5.0	0
219	Assessing the integrity of the dopamine system in Parkinson's disease: How best to do it?. Movement Disorders, 2001, 16, 804-806.	3.9	6
220	Pharmacodynamic modeling of oral levodopa in Parkinson's disease. Annals of Neurology, 2001, 50, 687-688.	5.3	3
221	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Annals of Neurology, 2001, 49, 298-303.	5.3	205
222	Apomorphine-Induced Changes in Synaptic Dopamine Levels: Positron Emission Tomography Evidence for Presynaptic Inhibition. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 1151-1159.	4.3	52
223	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Annals of Neurology, 2001, 49, 298-303.	5.3	85
224	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Annals of Neurology, 2000, 47, 493-503.	5.3	515
225	Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity. Synapse, 2000, 37, 171-178.	1.2	19
226	Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. Journal of Neural Transmission, 2000, 107, 49-57.	2.8	61
227	Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience, 2000, 98, 61-67.	2.3	12
228	Dopamine D1A receptor function in a rodent model of tardive dyskinesia. Neuroscience, 2000, 101, 629-635.	2.3	24
229	Nigrostriatal dopamine system and motor lateralization. Behavioural Brain Research, 2000, 112, 63-68.	2.2	76
230	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Annals of Neurology, 2000, 47, 493-503.	5.3	329
231	Unilateral pallidotomy for reduction of parkinsonian pain. Journal of Neurosurgery, 1999, 91, 198-201.	1.6	55
232	Etiology of Parkinson's Disease. Canadian Journal of Neurological Sciences, 1999, 26, S5-S12.	0.5	23
233	Differential Diagnosis of Parkinsonism. Canadian Journal of Neurological Sciences, 1999, 26, S1-S4.	0.5	7
234	Age-dependent decline of dopamine D1 receptors in human brain: A PET study. , 1998, 30, 56-61.		203

#	Article	IF	CITATIONS
235	Effect of age on caudate dopaminergic function in idiopathic Parkinsonism. Parkinsonism and Related Disorders, 1998, 4, 1-5.	2.2	6
236	Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [¹¹ C]-raclopride and positron-emission tomography. Neurology, 1998, 50, 1028-1032.	1.1	67
237	Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). Current Opinion in Neurology, 1998, 11, 327-333.	3.6	15
238	A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. NeuroReport, 1997, 8, 669-672.	1.2	29
239	Pallidotomy for tardive dyskinesia. Lancet, The, 1997, 349, 777-778.	13.7	43
240	The Neurotensin Antagonist SR 48692 Fails to Modify the Behavioural Responses to a Dopamine D1 Receptor Agonist in the Rat. Neuropharmacology, 1997, 36, 93-99.	4.1	5
241	The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCKA receptor antagonist: Evidence for a novel CCK receptor subtype?. Neuropharmacology, 1997, 36, 1679-1688.	4.1	4
242	Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum. Neuroscience, 1997, 76, 1173-1185.	2.3	5
243	Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. European Journal of Pharmacology, 1996, 298, 7-15.	3.5	8
244	Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade. Parkinsonism and Related Disorders, 1996, 2, 167-175.	2.2	3
245	Effects of ethanol in a putative rodent model of tardive dyskinesia. Pharmacology Biochemistry and Behavior, 1996, 54, 541-546.	2.9	4
246	Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. , 1996, 24, 256-261.		17
247	Environmental Exposures in Elderly Canadians With Parkinson's Disease. Canadian Journal of Neurological Sciences, 1995, 22, 232-234.	0.5	30
248	Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. Brain Research, 1995, 700, 115-120.	2.2	13
249	Absence of Mutations in Superoxide Dismutase and Catalase Genes in Patients With Parkinson's Disease. Archives of Neurology, 1995, 52, 1160-1163.	4.5	36
250	Effects of neurotensin in a rodent model of tardive dyskinesia. Neuropharmacology, 1995, 34, 457-462.	4.1	21
251	Localization of striatal and nigral tachykinin receptors in the rat. Brain Research, 1994, 646, 13-18.	2.2	47
252	Dopamine D1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone. European Journal of Pharmacology, 1994, 259, 301-303.	3.5	17

#	Article	IF	CITATIONS
253	The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Movement Disorders, 1993, 8, 445-452.	3.9	18
254	Neuroleptic-induced chewing movements in the rat are suppressed by peripherally but not centrally administered CCK and abolished by bilateral subdiaphragmatic vagotomy. Neuropharmacology, 1993, 32, 555-560.	4.1	5
255	Effects of ageing on tachykinin function in the basal ganglia. Brain Research, 1993, 632, 21-28.	2.2	13
256	Prevention and Management of Late Stage Complications in Parkinson's Disease. Canadian Journal of Neurological Sciences, 1992, 19, 113-116.	0.5	11
257	Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat. Brain Research, 1991, 558, 289-295.	2.2	17
258	Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Research, 1991, 565, 254-262.	2.2	54
259	Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide. Brain Research, 1990, 534, 1-7.	2.2	74
260	Pharmacological characterization of the behavioral syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT. Brain Research, 1990, 517, 111-116.	2.2	40
261	Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders. Journal of Psychopharmacology, 1989, 3, 99-120.	4.0	17
262	Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists. Psychopharmacology, 1989, 98, 372-379.	3.1	56
263	Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy. Brain Research, 1989, 495, 20-30.	2.2	42
264	The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation. Psychopharmacology, 1988, 95, 502-6.	3.1	17
265	The NKâ€3 tachykinin receptor agonist senktide elicits 5â€HTâ€mediated behaviour following central or peripheral administration in mice and rats. British Journal of Pharmacology, 1988, 94, 285-287.	5.4	59
266	Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse. Neuroscience Letters, 1987, 80, 321-326.	2.1	34
267	Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra. Psychopharmacology, 1987, 93, 336-42.	3.1	40
268	Controlling for Cerebral Atrophy in Positron Emission Tomography Data. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 510-512.	4.3	11
269	Regression Model for Predicting Dissociations of Regional Cerebral Glucose Metabolism in Individuals at Risk for Huntington's Disease. Journal of Cerebral Blood Flow and Metabolism, 1986, 6, 756-762.	4.3	19
270	DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS. Lancet, The, 1986, 328, 245-247.	13.7	727

#	Article	IF	CITATIONS
271	Dementia in Movement Disorders. Canadian Journal of Neurological Sciences, 1986, 13, 546-558.	0.5	7
272	Cerebral metabolism of glucose in benign hereditary chorea. Movement Disorders, 1986, 1, 33-44.	3.9	40
273	Glucose Use Correlations: A Matter of Inference. Journal of Cerebral Blood Flow and Metabolism, 1986, 6, 511-512.	4.3	29
274	Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics Stroke, 1985, 16, 734-736.	2.0	72
275	Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature, 1985, 317, 246-248.	27.8	309
276	Nemaline Myopathy With Associated Cardiomyopathy. Archives of Neurology, 1985, 42, 1084.	4.5	32
277	(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM. Lancet, The, 1985, 326, 1330-1331.	13.7	33
278	Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal microsomes. Prostaglandins, 1977, 14, 819-827.	1.2	38
279	Neuroimaging of Parkinson's disease and multiple system atrophy in patients with sleep disturbance. , 0, , 305-315.		0